Ipsapirone (TVX Q 7821, 2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1,2-benzisothiazol-3- (2H)one-1, 1-dioxidehydrochloride), a new
anxiolytic drug in respect of the evaluation of its effect on central
5-hydroxytryptamine (5-HT),
noradrenaline and
dopamine functions was studied. It was found that
ipsapirone inhibits induced by
8-OH-DPAT and 5-methoxydimethyltryptamine (agonists of 5-HT1A receptors) behavioural effects (flat body posture and forepaw treading) in normal and reserpinized rats.
Ipsapirone partly inhibited in rats but not in mice the 8-OH-DPAT-induced
hypothermia.
Ipsapirone, administered at high doses, decreased the body temperature in rats and mice, inhibited the 5-hydroxytryptophan-induced head twitches in mice and the
tryptamine-induced convulsions and
tremor in rats. In the hind limb flexor reflex preparation of the spinal rat only high doses of the
drug inhibited stimulation induced by
quipazine, m-chlorphenylpiperazine,
8-OH-DPAT and
St 587 (an agonist of alpha 1-
adrenoceptors).
Ipsapirone did not block the
fenfluramine- and m-chlorphenylpiperazine-
induced hyperthermia in rats at an ambient temperature of 28 degrees C. The
drug did not affect
clonidine-induced sedation and inconsiderably attenuated
clonidine-
induced hypothermia in mice. It attenuated the
d-amphetamine-induced locomotor hyperactivity in mice and rats but, given alone, decreased the locomotor activity. The obtained results indicate that
ipsapirone exhibits 5-HT1A antagonistic effect, and only at high doses it can also produce an inhibitory effect on 5-HT2 and the alpha 1-adrenergic function.